Inflammation markers and prediction of post-stroke vascular disease recurrence: The MITICO study
Tóm tắt
Vascular disease recurrence following stroke is the main cause of morbidity and mortality. The MITICO study was designed to assess the prognostic value of markers of inflammation in relation to the risk of recurrence of vascular disease. Multi-centered prospective observational study, in patients with ischemic stroke not receiving anti-coagulation therapy and who were recruited within 1–3 months from stroke onset. Blood samples were obtained at baseline and follow- up for the determination of high-sensitive C reactive protein (CRP), IL-6, IL-10, ICAM-1, VCAM- 1, MMP-9 and cellular fibronectin. Four follow-up visits within the first year were to rule out recurrence. Of 965 patients from 65 hospitals, 780 (aged 67.5±11.2 years, 33.6 % female) were valid for main analysis. One-hundred and three patients (13.2 %) had a new adverse vascular event and 116 patients (14.9 %) a vascular event or vascular death (66.4 % stroke, 21.5 % coronary and 12.1 % peripheral). Levels of IL-6 > 5 pg/mL and VCAM-1 > 1350 ng/mL (ROC curve analyses) were associated with vascular disease recurrence risk (OR: 28.7; 95 % CI: 14.2–58.0 vs. OR: 4.1; 95 % CI: 2.4–7.1, respectively) following adjustment for confounding variables. Risk of adverse vascular event or death from vascular disease were associated with IL-6 (OR: 21.2; 95 % CI: 11.6–38.7) and VCAM-1 (OR: 3.8; 95 % CI: 2.3–6.4). Baseline values of IL-6 > 5 pg/mL and VCAM-1 > 1350 ng/mL increase 21-fold and 4-fold, respectively, the risk of new vascular disease event or death from vascular disease in patients with ischemic stroke not receiving anti-coagulation treatment.
Tài liệu tham khảo
Arboix A, Garcia-Eroles L, Oliveres M, Massons JB, Targa C (1998) Clinical predictors of early embolic recurrence in presumed cardioembolic stroke. Cerebrovasc Dis 8:345–353
Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Eng J Med 355:549–559
Appelros P, Nydevik I, Viitanen M (2003) Poor outcome after first-ever stroke. Predictors for death, dependency, and recurrent stroke within the first year. Stroke 34:122–126
Blanco M, Rodriguez-Yanez M, Sobrino T, Leira R, Castillo J (2005) Platelets, inflammation, and atherothrombotic neurovascular disease: the role of endothelial dysfunction. Cerebrovasc Dis 20(Suppl 2):32–39
Bonetti PO, Lerman LO, Lerman A (2003) Endothelial dysfunction. A marker of atherosclorotic risk. Arterioscler Thromb Vasc Biol 23:168–175
Brown RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO (1996) Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota through 1989. Stroke 27:373–380
CAPRIE Steering Committee (1996) A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339
Castillo J, Leira R (2001) Predictors of deteriorating cerebral infarct: role of inflammatory mechanisms. Would its early treatment be useful? Cerebrovasc Dis 11(Suppl 1):40–48
Castillo J, Moro MA, Blanco M, Leira R, Serena J, Lizasoain I, Davalos A (2003) The release of tumor necrosis factor-α is associated with ischemic tolerance in human stroke. Ann Neurol 54:811–819
Chamorro A, Hallenbeck J (2006) The harms and benefits of inflammatory and immune response in vascular disease. Stroke 37:291–293
Chrysant SG, Chrysant GS (2006) The pleiotropic effects of angiotensin receptor blokers. J Clin Hypertens 8:261–268
Comite ad hoc del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Espanola de Neurologia (2004) Guia para el diagnostico y tratamiento del ictus. Prous Science, Barcelona
Coull BM (2007) Inflammation and stroke. Stroke 38(part 2):631
Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003
Davi G, Santilli F (2006) Unveiling the inflammatory face of antiplatelet drugs. J Thromb Haemost 4:2137–2139
Deveraj S, Rogers J, Jialal I (2007) Statins and biomarkers of inflammation. Curr Atheroscler Rep 9:33–41
Dhamoon MS, Sciacca RR, Rundek T, Sacco RL, Elkind MSV (2006) Recurrent stroke and cardiac risk after first ischemic stroke. The Northern Manhattan Study. Neurology 66:641–646
Dorrance AM, Rupp NC, Nogueira EF (2006) Mineralocorticoid receptor activation causes cerebral vessel remodeling and exacerbates the damage caused by cerebral ischemia. Hypertension 47(part 2):590–595
Elneihoum AM, Goransson M, Falke P, Janzal L (1998) Three-year survive and recurrence after stroke in Malmo, Sweden: an analysis of stroke registry data. Stroke 29:2114–2117
Friday G, Alter M, Lai S-M (2002) Control of hypertension and risk of stroke recurrence. Stroke 33:2652–2657
Gilbert RE, Rumble JR, Cao Z, Cox AJ, van Eeeden P, Allen TJ, Kelly DJ, Cooper ME (2000) Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hyperthrophy, and epidermal growth factor expression in experimental diabetes. Cir Res 86:158–165
Hankey GJ, Jamrozik K, Broadhurst RF, Forbes S, Burvill PW, Anderson CS, Stewart-Wynne EC (1998) Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 29:2491–2500
Harris AK, Hutchinson JR, Sachidanandam K, Johnson MH, Dorrance AM, Stepp DW, Fagan SC, Ergul A (2005) Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis. Role of endothelin-1. Diabetes 54:2638–2644
Hillen T, Coshall C, Tilling K, Rudd AG, McGovern R, Wolfe CDA (2003) Cause of stroke recurrence is multifactorial. Patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke 34:1457–1463
Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS (1997) Stroke recurrence: Predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology 48:891–895
Kang D-W, Lattimore SU, Latour LL, Warach S (2006) Silent ischemic lesion recurrence on magnetic resonance imaging predicts subsequent clinical vascular events. Arch Neurol 63:1730–1733
Lai SM, Alter M, Friday G, Sobel E (1994) A multifactorial analysis of risk factors for recurrence of ischemic stroke. Stroke 25:958–962 29. Libby P, Ridker PM, Maseri A (2002) Inflammation and aterosclerosis. Circulation 105:1135–1147
Leira EC, Chang K-C, Davis PH, Clarke WR, Woolson RF, Hansen MD, Adams HP Jr (2004) Can we predict early recurrence in acute stroke? Cerebrovasc Dis 18:139–144
Libby P, Ridker PM, Maseri A (2202) Inflammation and aterosclerosis. Circulation 105:1135–1147
Lisabeth LD, Smith MA, Brown DL, Moye LA, Risser JMH, Morgenstern LB (2006) Ethnic differences in stroke recurrence. Ann Neurol 60:469–475
Liu L, Ikeda K, Yamori Y (2001) Changes in stroke mortality rates for 1950 to 1997: A great show-down of decline trend in Japan. Stroke 32:1745–1749
Moroney JT, Bagiella E, Paik MC, Sacco RL, Desmond DW (1998) Risk factors for early recurrence after ischemic stroke. The role of stroke syndrome and subtype. Stroke 29:2118–2124
Niessen LW, Barendregt JJ, Bonneux L, Kousstaal PJ (1993) Stroke trends in an aging population. Stroke 24:931–939
PROGRESS Collaborative Group (2001) Randomized trial of a perindopril- based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 358:1033–1041
Ross GW, Petrovitch H, White LR, Masaki KH, Li CY, Curb JD, Yano K, Rodriguez BL, Foley DJ, Blanchette PL, Havlik R (1999) Characterization of risk factors for vascular dementia: the Honolulu-Asia Aging Study. Neurology 53:337–343
Sacco RL, Foulkes MA, Mohr JP, Wolf PA, Hier DB, Price TR (1989) Determinants of early recurrence of cerebral infarction. The Stroke Data Bank. Stroke 20:983–989
Shaya FT, El Khoury AC, Mullius CD, Du D, Skolasky R, Fatodu H, Garber H, Weir MR (2006) Drug therapy persistence and stroke recurrence. Am J Manag Care 12:313–319
Stegmayr B, Asplund K (1996) Exploring the declining case fatality in acute stroke: population-based observations in the northern Sweden MONICA Project. J Intern Med 240:143–149
Sundstrom J, Vasan RS (2006) Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol 17:45–53
Yokota C, Minematsu K, Hasegawa Y, Yamaguchi T (2004) Long-term prognosis, by stroke subtypes, alter a firstever stroke: A hospital-based study over a 20-year period. Cerebrovasc Dis 18:111–116